US Stock MarketDetailed Quotes

CC The Chemours

Watchlist
  • 16.690
  • -0.020-0.12%
Close Jan 3 16:00 ET
  • 16.730
  • +0.040+0.24%
Post 20:01 ET
2.49BMarket Cap33.38P/E (TTM)

The Chemours Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

The Chemours Q3 2024 Earnings Date

Currency：USDNov 4, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
1.44B
1.50B
+59.20M
Beat Est.
-3.04%
+0.94%
+4.11%
EPS
0.24
-0.18
-0.42
Miss Est.
--
-325.00%
-175.00%
Analyst Rating
Buy

Jan 4, 2025

The Chemours Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 1.412B--
--2024/Q4-- / 1.368B--
Nov 4, 20242024/Q31.501B / 1.442B--
Aug 1, 20242024/Q21.538B / 1.530B--
Apr 30, 20242024/Q11.350B / 1.410B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 1.412B--
--2024/Q4-- / 1.368B--
Nov 4, 20242024/Q31.501B / 1.442B--
Aug 1, 20242024/Q21.538B / 1.530B--
Apr 30, 20242024/Q11.350B / 1.410B--

Unlock Free Earnings Estimates

The Chemours Earnings Reports

  • The Chemours | 10-Q: Q3 2024 Earnings Report

    Nov 4, 2024 06:44 ET

  • The Chemours | 8-K: The Chemours Company Reports Third Quarter 2024 Results and Outlines Refreshed Corporate Strategy

    Nov 4, 2024 06:09 ET

  • The Chemours | 10-Q: Q2 2024 Earnings Report

    Aug 1, 2024 17:12 ET

  • The Chemours | 8-K: The Chemours Company Reports Second Quarter 2024 Results

    Aug 1, 2024 16:22 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    DexCom
    DXCM
    +3.27%
    Collegium Pharmaceutical
    COLL
    +3.07%
    Lantheus
    LNTH
    +2.71%
    Cars.com
    CARS
    +1.72%
    YETI Holdings
    YETI
    +1.60%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Jan 4, 2025

    Buy

    • Buy

      42.86%

    • Hold

      57.14%

    • Sell

      0.00%

    Price Target

    No Data